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Secondary Release of Exosomes From Astrocytes Contributes to the Increase  
in Neural Plasticity and Improvement of Functional Recovery After Stroke  
in Rats Treated With Exosomes Harvested From MicroRNA 133b-
Overexpressing Multipotent Mesenchymal Stromal Cells
Hongqi Xin,* Fengjie Wang,* Yanfeng Li,* Qing-e Lu,* Wing Lee Cheung,† Yi Zhang,* 
 Zheng Gang Zhang,* and Michael Chopp*‡
*Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
†Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI, USA
‡Department of Physics, Oakland University, Rochester, MI, USA
We previously demonstrated that multipotent mesenchymal stromal cells (MSCs) that overexpress microRNA 
133b (miR-133b) significantly improve functional recovery in rats subjected to middle cerebral artery occlusion 
(MCAO) compared with naive MSCs and that exosomes generated from naive MSCs mediate the therapeu-
tic benefits of MSC therapy for stroke. Here we investigated whether exosomes isolated from miR-133b-
overexpressing MSCs (Ex-miR-133b+) exert amplified therapeutic effects. Rats subjected to 2 h of MCAO 
were intra-arterially injected with Ex-miR-133b+, exosomes from MSCs infected by blank vector (Ex-Con), or 
phosphate-buffered saline (PBS) and were sacrificed 28 days after MCAO. Compared with the PBS treatment, 
both exosome treatment groups exhibited significant improvement of functional recovery. Ex-miR-133b+ treat-
ment significantly increased functional improvement and neurite remodeling/brain plasticity in the ischemic 
boundary area compared with the Ex-Con treatment. Treatment with Ex-miR-133b+ also significantly increased 
brain exosome content compared with Ex-Con treatment. To elucidate mechanisms underlying the enhanced 
therapeutic effects of Ex-miR-133b+, astrocytes cultured under oxygen- and glucose-deprived (OGD) condi-
tions were incubated with exosomes harvested from naive MSCs (Ex-Naive), miR-133b downregulated MSCs 
(Ex-miR-133b−), and Ex-miR-133b+. Compared with the Ex-Naive treatment, Ex-miR-133b+ significantly 
increased exosomes released by OGD astrocytes, whereas Ex-miR-133b− significantly decreased the release. 
Also, exosomes harvested from OGD astrocytes treated with Ex-miR-133b+ significantly increased neurite 
branching and elongation of cultured cortical embryonic rat neurons compared with the exosomes from OGD 
astrocytes subjected to Ex-Con. Our data suggest that exosomes harvested from miR-133b-overexpressing 
MSCs improve neural plasticity and functional recovery after stroke with a contribution from a stimulated 
secondary release of neurite-promoting exosomes from astrocytes.
Key words: MicroRNA 133b (miR-133b); Exosome; Multipotent mesenchymal stromal cell (MSCs); 
Neural plasticity; Astrocyte; Stroke; Functional recovery
INTRODUCTION
Multipotent mesenchymal stromal cells (MSCs) 
enhance functional recovery in experimental stroke models 
by amplifying neurogenesis, angiogenesis, and neural 
plasticity1–5. Our prior in vitro and in vivo studies indi-
cated that the therapeutic benefits of MSC-based therapies 
are mediated by exosome-enriched extracellular particles 
that transfer microRNAs (miRNAs) from MSCs to neural 
cells6–10. This exosome transfer of miRNAs evokes neurite 
remodeling and brain plasticity and subsequently benefits 
functional recovery6,8. Treatment of rats subjected to mid-
dle cerebral artery occlusion (MCAO) with MSCs over-
expressing microRNA 133b (miR-133b) augments neurite 
remodeling and brain plasticity and subsequently improves 
functional recovery6. Whether treatment of stroke with cell-
free exosomes enriched with miR-133b affects brain plas-
ticity and neurological recovery has not been investigated.
Exosomal release is regulated by specific physiologi-
cal and pathological conditions11–13 and by multivesicular 
body (MVB) fusion with the plasma membrane. Factors 
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that impact MVB fusion affect exosome secretion, for 
example, intracellular calcium14–16, K+-induced depolar-
ization15, and glutaminergic activity17. Extracellular exo-
somes may also impact the exosomes released by the 
recipient cells. An in vitro study has shown that exosomes 
from normal human mammary epithelial cells inhibit 
exosome secretion from breast cancer cells by means of 
negative feedback control after intake of the epithelial 
cell exosomes by breast cancer cells18.
Here we intra-arterially (IA) administered miR-133b-
enriched exosomes derived from MSCs to rats subjected 
to MCAO and investigated whether these exosomes exert 
amplified therapeutic effects compared with the control 
MSC exosomes. We demonstrated that exosomes tailored 
with enriched miR-133b from MSCs enhance neurological 
recovery and plasticity poststroke compared with the con-
trol MSC exosomes. We further demonstrated, for the first 
time, using in vivo and in vitro approaches, that miR-133b- 
enriched exosomes amplify neurite outgrowth poststroke 
by stimulating secondary release of astrocytic exosomes.
MATERIALS AND METHODS
All experimental procedures were carried out in 
accordance with the National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals and 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Henry Ford Health System. 
All exosome-enriched extracellular vesicles (EVs) were 
collected using multistep ultracentrifugation, and their 
sizes were verified by transmission electron microscopy 
as well as Western blot detection of common exosomal 
proteins, CD6319,20 and CD8121,22. For simplification, in 
the present study, we refer to these EVs as exosomes.
Production for miR-133b Knockin or Knockdown  
MSC Exosomes
MSCs (three to four passages (P3~4)] were dissoci-
ated from Wistar rat bone marrow, cultured, and then 
infected with lentivirus, as previously described6,23–25. The 
lentivirus was constructed with the vectors of LentimiRa-
GFP-hsa-miR-133b Vector (mh10170; pre-miR-133b 
was inserted for miR-133b knockin, Lenti-miR-133b+; 
Applied Biological Materials Inc., Richmond, Canada), 
pLenti-III-miR-GFP Control Vector (m001; vector for 
miR-133b knockin control, Lenti-miR-CON+; Applied 
Biological Materials Inc.), miRZip-133b anti-miR-133b 
miRNA construct (MZIP133b-PA-1; miR-133b inhib-
itor inserted for miR-133b knockdown, Lenti-miR-
133b−; System Biosciences, LLC, Palo Alto, CA, USA), 
and pGreenPuro Scramble Hairpin Control Con-
struct (MZIP000-PA-1; vector for miR-133b knock-
down control, Lenti-miR-CON−; System Biosciences, 
Inc.), respectively, according to the manufacturer’s 
suggested protocol. MSCs were infected with lentivirus 
when they achieved 80%–90% confluence and were 
selected by puromycin for constant gene expression. 
Correspondingly, the MSCs generated are referred to as 
miR-133b+MSCs, miR-CON+MSCs, miR-133b−MSCs, and 
miR-CON−MSCs, respectively. For the harvesting of exo-
somes, we replaced conventional culture medium with an 
exosome-depleted fetal bovine serum (FBS; EXO-FBS-
250A-1; System Biosciences, Inc.) medium when the cells 
reached 60%–80% confluence. After an additional 24 h of 
culturing, the media were then collected and centrifuged 
at 3,000 ´  g for 30 min to remove the dead cells and large 
cell apoptotic bodies; then the upper media were stored in 
a −80°C freezer for exosome isolation.
MCAO Model, Exosome Treatment,  
and Behavioral Tests
In our previous in vivo stroke studies, we administered 
exosomes intravenously7. In addition, we have shown that 
direct application of MSC exosomes on cultured cortical 
neurons induces neurite outgrowth via transfer of miR-
133b8. In the current study, in order to reduce the poten-
tial liver and lung sequestration of exosomes26,27 and to 
optimize the MSC exosome localization with neural 
parenchymal cells, we administered the exosomes using 
an IA approach.
Adult male Wistar rats (weighing 270–300 g) were 
purchased from Charles River Laboratories (Wilmington, 
MA, USA) and were subjected to 2 h of MCAO using 
a method of intraluminal vascular occlusion as modi-
fied in our laboratory28,29. Briefly, rats were anesthetized 
with 3.5% isoflurane for induction and maintained by 
spontaneously respired 1.0% isoflurane in a 2:1 N2O/O2 
mixture using a face mask. The rectal temperature was 
kept at 37 ± 1°C throughout the surgical procedure using 
a feedback-regulated water-heating system. MCAO was 
induced by advancing a 4-0 surgical nylon suture, with 
its tip rounded by heating near a flame, from the external 
carotid artery into the lumen of the internal carotid artery 
(ICA) to block the origin of the right middle cerebral 
artery (MCA). After 2 h of MCAO, animals were reanes-
thetized with isoflurane, and reperfusion was performed 
by withdrawal of the suture until the tip cleared the lumen 
of the external carotid artery. The procedure provides a 
focal infarct in the unilateral striatum and cortex28,30.
Twenty-four hours after induction of stroke, rats were 
randomly administered exosomes (3 ´  1011 particles, com-
parable to 100 µg of total exosome protein, per rat) 
harvested from miR-CON+MSCs (Ex-Con) or from miR-
133b+MSCs (Ex-miR-133b+) dissolved into 0.5 ml of 
phosphate-buffered saline (PBS; Thermo Fisher Scientific 
Inc., Grand Island, NY, USA) or 0.5 ml of PBS as vehicle 
control (n = 6/group).
For evaluation of functional recovery, a foot fault test31 
and a modified neurologic severity score (mNSS) test32 
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were performed prior to MCAO and 1, 3, 7, 14, 21, and 
28 days after MCAO by an investigator blinded to the 
treatments. All rats were sacrificed 28 days after MCAO. 
Rat brains were snap frozen in liquid nitrogen, and the 
frozen coronal sections were cut (40-µm thickness for 
molecular studies, e.g., Western blot and exosome extrac-
tion; 8-µm thickness for immunohistochemical staining) 
and stored in −80°C for subsequent analysis.
Exosome Isolation and Quantification
Exosome isolation from the cell cultured media was 
performed at 4°C via multistep centrifugation, as pre-
viously described7,8,33. Briefly, the stocked cultured cell 
media were thawed and followed by vortex mixing for 
1 min before centrifugation, and then centrifuged at 
10,000 ´  g for 30 min to remove large debris. The superna-
tants were filtered through a 0.22-µm filter (SLMP025SS; 
EMD Millipore Corporation, Billerica, MA, USA) to 
remove small cell debris, and the resulting media were 
further centrifuged at 100,000 ´  g for 2 h. By this step, 
the pellets primarily contained exosomes33. The final exo-
some pellets harvested from 1 ´  107 cells were identified, 
as previously described8, and resuspended in 30 to 50 µl 
of PBS and stored at −80°C for further use.
Exosomes in the ischemic boundary zone (IBZ) were 
extracted by following a previously described protocol 
with modification34. Briefly, the IBZ tissues from frozen 
rat brain sections were collected and digested with 20 U/
ml papain (LS 03126; Worthington Biochemical Corp., 
Lakewood, NJ, USA) in Hibernate E solution (20 µl/
mg brain tissue; Life Technologies Corporation, Grand 
Island, NY, USA) for 15 min at 37°C. The brain tissue was 
gently homogenized in two volumes of cold Hibernate 
E solution. The brain homogenate was sequentially fil-
tered through a Falcon™ 40-µm mesh filter (Catalog No. 
08-771-1; Thermo Fisher Scientific, Hampton, NH, USA). 
Exosomes were isolated from the filtrate, as previously 
described15. Briefly, the filtrate was sequentially centri-
fuged at 300 ´  g for 10 min at 4°C, 2,000 ´  g for 10 min 
at 4°C, 10,000 ´  g for 30 min at 4°C and filtered through 
0.2-µm syringe filters to discard cells, membranes, and 
debris. The supernatant was centrifuged at 100,000 ´  g for 
2 h at 4°C to pellet exosomes. The exosome pellet was 
resuspended in cold PBS, and the exosome solution was 
centrifuged at 100,000 ´  g for 2 h at 4°C.
Exosomes were identified by the marker protein 
CD6319,20 or CD8121,22 using Western blot, as well as 
by transmission electron microscopy (TEM) to verify 
the exosome size35,36. We quantitated the exosomes by 
measuring the total protein concentration, assessed by 
the micro bicinchoninic acid (BCA) protocol (Pierce, 
Rockford, IL, USA)37 and by a qNano particle analyzer 
(Izon Science Ltd., Cambridge, MA, USA) for exosome 
particle number.
In Vitro Primary Astrocyte Culture and Treatments
Extracts from cortices of embryonic day 18 Wistar rats 
(either sex; Charles River Laboratories) were dissociated 
into a cell suspension using mechanical digestion. After 
digestion, cells were plated in 75-cm2 tissue culture flasks 
at a concentration of 1.5 ´  107 cells in Dulbecco’s modified 
Eagle’s medium (DMEM; Catalog No. 11995-065; Thermo 
Fisher Scientific) containing 20% FBS. The flasks were 
incubated at 37°C in a moist 5% CO2, 95% air atmosphere 
for 48–72 h before moving. The medium was changed 
every 48–72 h. After incubating the primary cultures for 
7–9 days, the flasks were placed on a shaker platform in 
a horizontal position with the medium covering the cells 
and were shaken at 350 rpm for 6 h at 35°C to separate oli-
godendrocytes from the astrocytes. Medium was changed 
and flasks were placed on the shaker for an additional 18 h. 
Afterward, medium was again changed and shook for an 
additional 24 h. When confluent, cells were passed and used 
for MSC exosome treatment. To mimic the in vivo ischemic 
condition, an in vitro oxygen- and glucose-deprived (OGD) 
culture system on astrocytes was employed, as previously 
described38. Primary cultured astrocytes were washed twice 
with PBS before MSC exosome treatment, and then the 
media containing exosomes (3 ´  1010 particles/ml) or media 
alone were added to the cultured cells.
Neurite Outgrowth Assay
Primary cultures of cortical neurons were harvested 
from embryonic day 18 Wistar rats, as previously 
described39: Pregnant rats purchased from Charles River 
Laboratories were euthanized under deep pentobarbi-
tal anesthesia. Embryos were removed, and the cerebral 
cortex was dissected out, washed in Hank’s balanced salt 
solution (HBSS; Gibco, Grand Island, NY, USA), and 
dissociated by a combination of 0.125% trypsin digestion 
for 15 min, then mechanically triturated 20 times. The 
triturated cells were passed through a 40-µm cell strainer 
and counted to obtain a concentration of 3 ´  107 cells/ml.
For the neurite outgrowth assay, the neurons were then 
plated overnight onto a poly(D-lysine)-coated 24-well 
plate at a density of 5,000 cells per well in DMEM con-
taining 5% FBS and antibiotics. After 24 h, cells were 
washed three times with PBS and treated with various 
astrocytic-derived exosomes dissolved at a concentration 
of 3 ´  1010 particles/ml into the serum-free neurobasal 
medium (Gibco) supplemented with 2% B-27 (Gibco), 
500 µM L-glutamine, and antibiotics (Catalog No. G6784; 
Sigma-Aldrich, St. Louis, MO, USA). After 3 days, neu-
rons were washed and fixed with 4% paraformaldehyde 
(PFA) and immunofluorescence staining for b-III-tubu-
lin (TuJ1) for neurite outgrowth analysis, as previously 
described39. Briefly, to analyze neurite outgrowth, TuJ1+ 
cells were digitized using a 20´ objective (Carl Zeiss 
Microscopy, LLC, Thornwood, NY, USA) via the Micro 
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Computer Imaging Device (MCID) analysis system 
(Imaging Research, St. Catharines, Canada). Neurite out-
growth was quantified using a software program devel-
oped in our laboratory that includes measurements of the 
number and length of branches40. At least 50 TuJ1+ cells, 
distributed in nine random fields per well, and triple wells 
per group were measured, and three independent experi-
ments were performed. All measurements were performed 
by experimenters blinded to each culture condition.
miRNA Assay
For the measurement of miR-133b in exosomes from 
cultured cells, samples were lysed in QIAzol reagents, 
and the total RNA was isolated using the miRNeasy Mini 
Kit (Qiagen, Valencia, CA, USA). By real-time poly-
merase chain reaction (RT-PCR), we detected the miR-
133b level. Briefly, miRNAs were reverse transcribed 
with the miRNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA), and PCR amplifica-
tion was performed with the TaqMan miRNA Assay Kit 
(which is specific for mature miRNA sequences; Applied 
Biosystems) according to the manufacturer’s protocols, 
with U6 snRNA as an internal control.
Histopathology and Immunohistochemistry
To determine neurite remodeling in the IBZ, adjacent 
frozen coronal sections of rat brains were used for stain-
ing the following markers, and positive staining within the 
IBZ was measured under light microscopy. Bielschowsky 
silver (silver nitrate; stains neuronal processes41; Sigma-
Aldrich) combined with Luxol fast blue (stains myelin 
sheath42; Sigma-Aldrich) histochemistry staining as well 
as immunostaining with antibodies against the phosphory-
lated epitope of neurofilament heavy polypeptide (NF-H), 
clone SMI 31 (SMI 31; reacts broadly with thick and thin 
axons and some dendrites43), and synaptophysin (a marker 
for synapses, since synaptophysin is ubiquitously present 
at the synapses44) were employed, respectively. Briefly, 
for immunostaining, adjacent frozen brain sections were 
incubated with the primary antibodies against SMI 31 
(1:500; ab82259; Abcam, Cambridge, MA, USA), syn-
aptophysin (1:100; MAB5258; Chemicon, Billerica, MA, 
USA), and BrdU (1:100; Roche Diagnostics Corporation, 
Indianapolis, IN, USA), followed with corresponding 
horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Abcam) and 3,3¢-diaminobenzidine (DAB; 
Sigma-Aldrich) devel oping, respectively. Positive stain-
ing within nine areas (four from the cortex, four from 
the striatum, and one from the corpus callosum) selected 
along the IBZ in these groups were digitized under a 40´ 
objective (BX40; Olympus Optical, Waltham, MA, USA) 
using a 3-CCD color video camera (DXC-970MD; Sony, 
Teaneck, NJ, USA) interfaced with the MCID™ soft-
ware45. For the analysis of neurite remodeling, based on 
evaluation of an average of three histology slides (8-µm 
thick, interval of every 10th slide) from the standard block 
of each animal, the percentage of positive staining area to 
the whole area of each image taken within the IBZ was 
analyzed using the MCID™ software.
To detect astrocytic expression of Rab9 effector pro-
tein with kelch motifs (RABEPK) in the IBZ, double 
immunofluorescence staining was employed to iden-
tify the cellular colocalization of RABEPK (1:100; 
sc-107078; Santa Cruz Biotechnology, Dallas, TX, USA) 
with glial fibrillary acidic protein (GFAP; a marker of 
reactive astrocyte; 1:10,000; Z0334; Dako, Carpinteria, 
CA, USA), followed by their corresponding second anti-
body staining [fluorescein isothiocyanate (FITC) labeled 
for RABEPK and Cy3 labeled for GFAP].
Statistical Analysis
Data are summarized and presented using mean ± 
standard error (SE). Post hoc tests were used for sub-
group analysis following analysis of variance (ANOVA). 
The Global test using the generalized estimating equa-
tion (GEE) was employed to evaluate the MSC exosome 
treatment effects influenced by miR-133b enrichment on 
functional recovery46,47. Repeated-measures analysis was 
used to evaluate data with repeated measurements over 
time (e.g., functional tests) or histological evaluation on 
multiple regions per subject. Analysis began testing for 
the factor interaction, followed by testing the main factor 
effect if no interaction was detected at the 0.05 level, and/
or a subgroup analysis was performed if the interaction or 
main effect was detected at the 0.05 level48. All statistical 
analyses were conducted using the SAS software (version 
9.2; SAS Institute, Cary, NC, USA).
RESULTS
miR-133b Level Modified by Lentivirus Introduction  
of Pre-miR-133b and miR-133b Inhibitors
Quantitative RT-PCR analysis showed that mature 
miR-133b levels in the MSCs infected by lentivirus car-
rying pre-miR-133b were increased and, concomitantly, 
miR-133b levels in exosomes harvested from these MSCs 
significantly increased (Table 1). Correspondingly, the 
miR-133b levels in MSCs and harvested exosomes were 
significantly decreased by introducing an miR-133b inhib-
itor into MSCs (Table 1). There was no statistical differ-
ence in miR-133b levels among naive MSCs and MSCs 
infected by blank vector controls (miR-CON+MSCs and 
miR-CON−MSCs) as well as in their corresponding exo-
somes (Table 1).
miR-133b-Enriched Exosomes Improve Neurological 
Outcome After MCAO
Tailored exosomes enriched with miR-133b as well 
as the exosomes harvested from blank vector control 
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MSCs administered IA to rats subjected to 2 h of tran-
sient MCAO significantly reduced neurological deficits 
compared with the PBS-treated rats. Foot fault and mNSS 
tests were performed to assess the sensorimotor function. 
All rats exhibited severe sensorimotor deficit at post-
operative day 1, followed by gradual improvement within 
the 4-week experimental course. Compared with the PBS 
treatment, both exosome treatment groups exhibited sig-
nificant improvement of functional recovery in the foot 
fault test (Fig. 1A) and mNSS (Fig. 1B); however, sig-
nificant improvement was detected at 7 and 14 days after 
MCAO in the Ex-miR-133b+ and the Ex-Con treatment 
groups, respectively. Compared with the Ex-Con, the 
Ex-miR-133b+ treatment significantly increased func-
tional improvement (p < 0.05 after day 21, respectively) 
(Fig. 1A and B).
miR-133b-Enriched Exosomes Enhance Neurite 
Remodeling in the IBZ
Stroke evokes partial damage and disorganization to 
axon–myelin bundles in the IBZ49. Double staining for 
Bielschowsky silver and Luxol fast blue was employed 
to identify axons and myelin in the white matter in the 
brain, respectively. Axonal density along the IBZ was 
 significantly increased by the exosome treatment com-
pared with the PBS control 28 days after MCAO, and 
Ex-miR-133b+ further increased the axonal density com-
pared with the Ex-Con (p < 0.05, respectively) (Fig. 2, 
row A).
The phosphorylation of the neurofilament (NF) is 
considered an important determinant of filament caliber, 
plasticity, and stability50. Immunocytochemically puri-
fied anti-NF-H phosphorylated antibody (clone SMI 31) 
reacts broadly with thick and thin axons and some den-
drites such as basket cell dendrites, but not Purkinje cell 
Figure 1. MicroRNA 133b (miR-133b)-enriched exosome treatment enhances neurological outcome improvement. Foot fault test 
(A) and modified neurologic severity score (mNSS) (B) data show that compared with the phosphate-buffered saline (PBS) treatment, 
both multipotent mesenchymal stromal cell (MSC) exosome treatment groups exhibited significant improvement of functional recov-
ery (p < 0.05 after day 14, respectively). Compared with the MSCs infected with blank vector (Ex-Con), exosomes isolated from miR-
133b-overexpressing MSCs (Ex-miR-133b+) significantly increased functional improvement (p < 0.05 after day 21, respectively). PBS, 
middle cerebral artery occlusion (MCAO) rats treated with PBS; CON+, MCAO rats treated with Ex-Con; 133b+, MCAO rats treated 
with Ex-miR-133b+; EXO, exosomes given. *p < 0.05, compared to PBS; #p < 0.05 compared to CON+, respectively. Mean ± standard 
error (SE), n = 6/group.
Table 1. Relative miR-133b Level in the Various Lentivirus-
Infected MSCs and Their Corresponding Exosomes
Groups
In Cells  
(Relative Fold)
In Exosomes  
(Relative Fold)
Naive MSCs 1.0 1.0
miR-CON+MSCs 1.01 ± 0.21 0.98 ± 0.23
miR-133b+MSCs 432.65 ± 125.01* 8.83 ± 2.31*
miR-CON−MSCs 1.02 ± 0.13 1.01 ± 0.34
miR-133b−MSCs 0.23 ± 0.19† 0.45 ± 0.11†
*p < 0.01 compared with the miR-CON+MSCs; †p < 0.05 compared with 
the miR-CON−MSCs.
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dendrites, and immunohistochemistry staining with this 
antibody reveals the accumulation of phosphorylated 
NF-H (p-NFH) in axons and dendrites in the peri-infarct 
region after stroke51. Our data showed that the exosome 
treatment significantly increased the p-NFH immuno-
reactive area in the IBZ compared with the PBS control 
28 days after MCAO, and similarly, Ex-miR-133b+ fur-
ther increased the p-NFH immunoreactivity compared 
with the Ex-Con (p < 0.05, respectively) (Fig. 2, row B).
Immunostaining data also showed that compared with 
the PBS control, the MSC exosome treatment significantly 
increased synaptophysin, a presynaptic vesicle protein that 
identifies synaptic plasticity and synaptogenesis52 in the 
IBZ 28 days after MCAO, while Ex-miR-133b+ further 
increased the synaptophysin immunoreactivity compared 
with the Ex-Con (p < 0.05, respectively) (Fig. 2, row C).
miR-133b-Enriched Exosomes Increase Exosomes  
in Ischemic Brain
Cellular release of vesicles containing functional com-
ponents (e.g., RNAs and proteins) that are taken up and 
incorporated into the target recipient cell has emerged 
as a regulatory mechanism for coordination of nervous 
system function53–55. Exosomes released by astrocytes 
and other glial cells in the central nervous system (CNS) 
likely modulate neuron–glial–vascular communication 
and support neural plasticity33,56–58. We therefore mea-
sured the amount of exosomes present in the IBZ. Our 
data show that the Ex-miR-133b+ treatment significantly 
increased the presence of exosomes in brain IBZ com-
pared with the Ex-Con treatment (p < 0.05) (Fig. 3C) and 
the PBS treatment.
miR-133b-Enriched Exosomes Increase the Release  
of Exosomes From Cultured Primary Astrocytes
Since astrocytes are the most abundant cells in the 
nervous system and play an active role in brain recov-
ery59–61, and OGD culture has been used as an in vitro 
model to mimic the in vivo ischemic condition62–64, we 
employed OGD-cultured astrocytes to elucidate mecha-
nisms underlying the enhanced therapeutic effects of 
Ex-miR-133b+ on rats subjected to MCAO. First, we 
investigated the effects of Ex-miR-133b+ on astrocyte 
exosomal release. OGD astrocytes were incubated with 
Ex-Naive, Ex-miR-133b−, and Ex-miR-133b+, as well as 
exosomes from miR-CON+MSCs and miR-CON−MSCs, 
and the release of exosomes from astrocytes was quanti-
fied. Our data showed that astrocytes subjected to OGD 
increased exosomal release, while MSC exosomes further 
significantly increased exosomes released by OGD astro-
cytes. There was no statistically significant difference of 
exosomes released by OGD astrocytes among the naive 
MSC exosomes and the two control MSC exosome treat-
ments (Fig. 4A). However, compared with the Ex-Naive 
treatment, Ex-miR-133b+ significantly increased exo-
somes released by OGD astrocytes (p < 0.05) (Fig. 4A), 
whereas incubation of OGD astrocytes with Ex-miR-
133b− significantly decreased the OGD astrocytes to 
release exosomes (p < 0.05) (Fig. 4B). In a complemen-
tary experiment, we also investigated the effect of over-
expression of miR-133b on MSCs to release exosomes. 
Infection of MSCs with the blank vector controls did not 
significantly affect MSCs to release exosomes compared 
to naive MSCs. However, overexpression or inhibition of 
miR-133b significantly increased or decreased, respec-
tively, MSC release of exosomes compared to naive 
MSCs (p < 0.05) (Fig. 4B).
Exosomes Harvested From OGD Astrocytes Treated 
With Ex-miR-133b+ Increase Neurite Outgrowth
By employing the primary cortical neuronal neurite 
outgrowth assay, we tested the effects of OGD astro-
cyte exosomes on neurite branching and elongation of 
the neurons. Our data show that exosomes harvested 
from OGD astrocytes significantly increased the neurite 
branch number and total neurite length per neuron com-
pared with the non-exosome-treated neurons. Compared 
to exosomes from astrocytes subjected to OGD only, 
exosomes harvested from OGD astrocytes pretreated 
by Ex-Con and Ex-miR-133b+ substantially increased 
the neurite branch number and total neurite length of 
Figure 3. MicroRNA 133b (miR-133b)-enriched exosomes 
increased exosomes in brain ischemic boundary zone (IBZ). 
Western blot shows that the common exosomal proteins CD63 
and CD81 are present in the exosome extraction from the IBZ 
(A). The transmission electron microscopic (TEM) images show 
the morphology of exosomes presented in the brain extracellu-
lar (B), within a size range of 30–100 nm. qNano quantifica-
tion data show that compared to the multipotent mesenchymal 
stromal cells (MSCs) infected with blank vector (Ex-Con) treat-
ment and phosphate-buffered saline (PBS) control, the extracel-
lular exosomes present in the IBZ significantly increased after 
miR-133b-overexpressing MSC (Ex-miR-133b+) treatment (C). 
PBS, middle cerebral artery occlusion (MCAO) rats treated with 
PBS; CON+, MCAO rats treated with Ex-Con; 133b+, MCAO 
rats treated with Ex-miR-133b+. *p<0.05, compared to Ex-Con. 
Mean ± standard error (SE), n = 6/group. Scale bar: 100 nm.
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primary cultured cortical neurons, while exosomes from 
OGD astrocytes treated by Ex-miR-133b+ employed to 
treat primary cortical neurons had more robust effects 
on neurite outgrowth compared with the exosomes from 
OGD astrocytes with Ex-Con (p < 0.05, respectively) 
(Fig. 5A–D).
miR-133b-Enriched Exosomes Downregulate  
the Protein Level of RABEPK
MVBs can either be routed to lysosomes for deg-
radation or to exosomes for secretion65. Lysosomal 
dysfunc tion increases exosomal release66,67; RABEPK, 
co operating with Rab9, participates in the endosome-to-
trans-Golgi network (TGN) transport, which is essential 
for the lysosome formation68. Using Western blot and 
immunohistochemistry staining of IBZ tissues, we there-
fore examined whether the exosomal treatment affects 
RABEPK. Our data revealed that ischemia increased 
RABEPK protein levels, whereas the Ex-Con treatment 
significantly reduced MCAO-increased RABEPK pro-
teins and the Ex-miR-133b+ treatment further decreased 
the protein level (p < 0.05, respectively) (Fig. 6A and B). 
Double immunofluorescence staining showed the RABEPK 
immunoreactivity was largely localized to GFAP+ astro-
cytes (Fig. 6E–H). We then employed OGD astrocytes to 
further examine the effect of MSC exosomes on RABEPK 
expression in astrocytes. We found that the Ex-Con treat-
ment significantly reduced RABEPK protein levels in 
the astrocytes subjected to OGD, and the Ex-miR-133b+ 
treatment further lowered the protein level (p < 0.05, 
respectively) (Fig. 6C and D).
DISCUSSION
Exosomes released by transplanted cells mediate 
the benefits of cell-based therapies for stroke6,8,69,70. It 
is therefore reasonable to consider replacing cell-based 
therapy for stroke with cell-free exosome-based treat-
ment, which would minimize potential adverse effects of 
administering replicating and embolism-forming cells71. 
We therefore employed exosomes harvested from naive 
MSCs to treat experimental stroke models and found that 
the therapeutic effects of exosomes were consistent with 
the therapeutic effects of direct MSC treatment7. In the 
current study, we extended this exosome therapy concept 
to tailor the miRNA content of the exosomes. On the 
basis of studies indicating that miR-133b promotes neu-
rovascular plasticity, we generated and employed exo-
somes enriched with miR-133b for the treatment of rats 
subjected to MCAO. We found that miR-133b-enriched 
exosomes significantly amplified the therapeutic benefits 
for stroke compared to control MSC exosomes. Our in 
vivo and in vitro studies also suggest that astrocytes and 
possibly other neural parenchymal cells participate in 
Figure 4. MicroRNA 133b (miR-133b)-enriched exosomes 
enhance the release of exosomes from primary cultured oxygen- 
and glucose-deprived (OGD) astrocytes. MSC exosomes sig-
nificantly increased the exosomes released by OGD astrocytes, 
and there was no obvious difference on the release from OGD 
astrocytes, after treatment with harvested from naive MSCs 
(Ex-Naive) and two control exosomes (A). Compared with the 
exosome Ex-Naive treatment, exosomes released by OGD astro-
cytes treated with miR-133b-overexpressing MSCs (Ex-miR-
133b+) were significantly increased (A) and significantly 
decreased (B) by treatment with Ex-miR-133b−, respectively. 
Correlated with the miR-133b levels in the multipotent mesen-
chymal stromal cells (MSCs) (Table 1), the number of exosomes 
released by MSCs has no difference between naive MSCs and 
the two control MSCs (miR-CON+MSCs and miR-CON−MSCs), 
but the exosomal release was significantly increased from the 
miR-133b+MSCs and decreased from the miR-133b−MSCs, 
compared with that from naive MSCs (B). NivM, naive MSCs; 
NivA, naive astrocytes; NON, nontreated OGD astrocytes; MSC, 
OGD astrocytes treated with naive MSC exosomes; CON−, miR-
CON−MSC or OGD astrocytes treated with miR-CON−MSC exo-
somes; 133b−, miR-133b−MSC or OGD astrocytes treated with 
miR-133b−MSC exosomes; CON+, miR-CON+MSC or OGD 
astrocytes treated with miR-CON+MSC exosomes; 133b+, miR-
133b+MSC or OGD astrocytes treated with miR-133b+MSC exo-
somes. *p < 0.05, mean ± SD, n = 3/group.
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the enhanced functional recovery for stroke induced by 
miR-133b-enriched exosomes. miR-133b increased the 
secondary release of exosomes from astrocytes, which 
appear to more potently enhance neurite outgrowth and 
plasticity than naive MSC exosomes. Thus, our study 
provides the basis for engineering miRNA content of 
exosomes that concurrently regulate multiple molecular 
pathways and further promote restorative processes, and 
that exosomes, whether naive or engineered, induce sec-
ondary release of astrocytic exosomes. Here we focused 
on astrocytes, and we do not exclude the possibility that 
other parenchymal and inflammatory or vascular cells 
may also release secondary exosomes in response to pri-
mary exosome stimulation.
EVs, including exosomes, are involved in intercellular 
communication within the nervous system54 and play major 
roles in neurological diseases and in nerve trauma72,73, 
as well as mediate signaling during brain development 
and function74. Exosomes released by brain parenchymal 
cells modulate neuron–glial–vascular communication and 
support neural plasticity33,56,57,75,76. By modulating the inter-
actions between glia and neurons, glial-derived exosomes 
promote neurite outgrowth and neuronal survival under 
high neuronal activity and/or oxidative stress condition33. 
miR-133b-enriched exosomes increased exosome con-
tent within the IBZ. This increase may be attributed to 
exosomes generated by astrocytes. However, as noted, 
we cannot exclude the possibility that the preferential 
increase of exosomes released by other neural paren-
chymal cells induced by miR-133b-enriched exosomes 
may also participate in the enhanced neural plasticity and 
functional recovery, since other brain parenchymal cells 
(e.g., oligodendrocytes) also secrete exosomes that contain 
major myelin- and stress- protective proteins, and these 
exosomes are involved in glia-mediated trophic support 
to axons16.
MVBs are generated by inward budding of the late 
endosomal membrane, which gives rise to intraluminal 
Figure 5. Exosomes harvested from oxygen- and glucose-deprived (OGD) astrocytes after treatment with miR-133b-overexpressing 
MSCs (Ex-miR-133b+) increase neurite outgrowth. (A) The morphology of cultured neurons in this assay. Exosomes harvested from 
OGD astrocytes significantly increased the neurite number and total neurite length per neuron compared with the non-exosome-
treated primary cultured cortical neurons. The neurite number and total neurite length substantially increased after the neurons were 
treated with exosomes harvested from OGD astrocytes that were pretreated by the MSCs infected with blank vector (Ex-Con) and 
Ex-miR-133b+, and Ex-miR-133b+-pretreated OGD astrocytic exosomes have the enhanced effect compared with the Ex-Con pretreat-
ment (p < 0.05, respectively; B–D). Con, non-exosome-treated neurons; OGD, neurons treated with exosomes harvested from OGD 
astrocytes; Con+, neurons treated with exosomes harvested from OGD astrocytes pretreated with Ex-Con; 133b+, neurons treated with 
exosomes harvested from OGD astrocytes pretreated with Ex-miR-133b+. *p < 0.05, mean ± standard deviation (SD), n = 3/group. Scale 
bar: 50 µm.
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Figure 6. MicroRNA 133b (miR-133b)-enriched exosomes downregulate the protein level of Rab9 effector protein with kelch motifs 
(RABEPK). Western blot data show that the MSCs infected with blank vector (Ex-Con) treatment significantly downregulated the 
RABEPK level increased in the ischemic boundary zone (IBZ) after middle cerebral artery occlusion (MCAO), and miR-133b-over-
expressing MSC (Ex-miR-133b+) treatment further reduces the protein level (A, B) (p < 0.05, respectively). Double immunostaining 
shows the RABEPK largely expressed in the astrocytes (E–H). Ex-Con treatment significantly reduced the RABEPK level increase 
in the astrocytes subjected to oxygen and glucose deprivation (OGD), and Ex-miR-133b+ treatment further reduces the protein level 
(C, D) (p < 0.05, respectively). Sham, tissue from sham surgery rats; PBS, MCAO rats treated with phosphate-buffered saline (PBS); 
Naive, naive astrocytes; OGD, astrocytes subjected to OGD; CON+, MCAO rats or OGD astrocytes treated with Ex-Con; 133b+, 
MCAO rats or OGD astrocytes treated with Ex-miR-133b+. *p < 0.05, mean ± standard deviation (SD), n = 3/group. Scale bar: 50 µm.
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vesicles (ILVs) within late endosomes65. MVBs can be 
either routed to lysosomes for degradation or fused with 
the plasma membrane to discharge their ILVs as exo-
somes to the extracellular space. Delivery of lysosomal 
enzymes is essential for the maintenance of proper func-
tioning lysosomes, which include addition of a specific 
lysosomal tag, mannose 6-phosphate (M6P), to peptides, 
for example, lysosomal hydrolases. With binding of these 
tags to M6P receptors in the Golgi apparatus and proper 
packaging into vesicles destined for the lysosomal sys-
tem, the hydrolases are released in the acidic environment 
of endosomes, and the receptor is retrieved to the Golgi 
by retromer and Rab977,78. RABEPK is required for this 
endosome-to-TGN transport68, so the lack of RABEPK 
may lead to reduced lysosome formation. Lysosomal dys-
function causes increased exosomal release66,67,79,80. Our 
data suggest that increased RABEPK level in the IBZ 
may consequently increase the lysosome formation. 
These data are consistent with prior studies showing 
that the autophagy and lysosomal degradation pathways 
are stimulated in hypoxia–ischemia-induced brain inju-
ry81–85. Endocytosis and autophagy cooperate and share 
molecular machinery, such as the Rab GTPase net-
work86–89. The structure of the autophagy pathway, the 
autophagosome, can fuse with endocytic structures such 
as MVBs to generate the amphisome, which fuses with 
the lysosome to degrade the material wrapped inside90–93. 
Hypoxia induces exosome release as well13,94. Impacting 
the balance between the autophagy and lysosome path-
ways, by inhibiting the lysosome formation, may increase 
the exosome release. The RABEPK expression was 
downregulated after miR-133b-enriched exosome treat-
ment in the IBZ may effect on increasing exosomal release 
from astrocytes. RABEPK is one of the putative genes 
targeted by miR-206 (Targetscan.org), while transform-
ing growth factor-b (TGF-b) inhibits miR-206 levels95. 
Although it does not directly target the RABEPK gene, 
miR-133b negatively regulates the TGF-b signal pathway 
activity96, which may lead to the decrease of RABEPK 
expression. Thus, further investigations on the regulation 
of miR-133b on miR-206 expression and subsequently on 
RABEPK protein level, as well as the balance of lyso-
some formation and exosome generation, are warranted.
Exosomes penetrate the brain–blood barrier (BBB)97,98; 
however, the detailed mechanisms are unclear. Trans-
cytosis in epithelial cells may participate in the process99,100. 
Transcytosis allows some materials to enter one side of 
a cell and exit from the opposite side. Possibly, in some 
circumstances, exosomes in the vessel lumen side may 
be endocytosed by the endothelial cell of the BBB to 
form as late endosomes/MVBs and then fuse with the 
plasma membrane instead of with lysosomes, releasing 
the engulfed exosomes, into the brain parenchymal side 
extracellular space. We administer the exosomes using an 
IA approach in the current study to reduce potential liver 
and lung sequestration. Interestingly, our previous study, 
which employed IV administration of naive MSC exo-
somes7, also showed beneficial effects on the stroke res-
toration, may suggest that in addition to directly affecting 
brain parenchymal cells, administration of exosomes may 
also have systemic effects that participate their restorative 
effects after stroke. Given that miR-133b-enriched exo-
somes increase the secondary release of exosomes from 
astrocytes, they may also interact with endothelial cells 
and increase the exosomes released by endothelial cells.
There are a number of caveats to consider. We have 
previously demonstrated that treatment of stroke with 
downregulated miR-133b in MSCs significantly reduces 
functional recovery after MCAO compared with naive 
MSC-treated animals, and treatment with MSCs enriched 
in miR-133b significantly enhances functional recovery 
compared with naive MSC-treated animals6. Importantly, 
our data indicated that the therapeutic effects were medi-
ated by exosome transfer of miR-133b from the MSCs 
to the brain. In the present study, our primary goal was 
to demonstrate, as a proof of principle, that we can fur-
ther improve functional recovery by administering tai-
lored exosomes enriched in miR-133b. Further studies, 
in which miR-133b exosome content is reduced to ver-
ify the function of exosomal miR-133b, are warranted. 
Although volumes of cerebral infarction are not altered 
by the MSCs and MSC exosome treatment2,7, we can-
not exclude the possibility that treatment with exosomes 
harvested from miR-133b-overexpressing MSCs at 24 h 
poststroke also evokes some neuroprotective benefits in 
the ischemic boundary region.
CONCLUSIONS
IA-administered exosomes harvested from miR-133b- 
overexpressing MSCs improve neural plasticity and 
functional recovery after stroke beyond that of naive exo-
somes. Exosomes enriched with mature miR-133b from 
miR-133b-overexpressing MSCs further stimulate and 
increase exosomes release from astrocytes, possibly by 
downregulating the RABEPK expression. The exosomes 
derived from OGD astrocytes pretreated with miR-133b-
enriched exosomes promote neurite outgrowth and elon-
gation in vitro. We thus propose that the contribution of 
the secondary astrocytic exosome release may contribute 
to brain plasticity and subsequent neurological recovery 
after stroke.
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